Comments
Panacea Biotec’s oncology parenteral formulations facility at Baddi, Himachal Pradesh, has received United States Food & Drug Administration approval for manufacture and supply of Azacitidine injection, 100 mg/vial, for the US market. The facility at Baddi has already been approved by the National Regulatory Authority of India and the USFDA for other oral solids and injectable products. Panacea Biotec had earlier entered into a tripartite agreement with Natco Pharma and Breckenridge Pharmaceutical for manufacture and supply of Azacitidine injection. Shares of Panacea Biotec gained 1 per cent at ₹192.40 on the NSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.